Hong Kong's Kidney Care Revolution: Why 'PD First' Is Saving Lives and Money
"Discover how a pioneering dialysis policy is transforming healthcare and improving outcomes for patients with kidney disease."
In the bustling city of Hong Kong, a quiet revolution is taking place within its healthcare system. It's a revolution driven by a simple, yet powerful, principle: prioritizing peritoneal dialysis (PD) for patients with kidney disease. This 'PD-first' policy, implemented for over three decades, has not only achieved remarkable success but also serves as a model for other regions grappling with the rising burden of end-stage renal disease (ESRD).
The numbers speak volumes. In Hong Kong, the average cost of hemodialysis (HD) per patient is more than double that of PD. As the prevalence of ESRD continues to rise globally, the financial strain on healthcare systems is immense. This article dives deep into the 'PD-first' policy, exploring its benefits, the challenges it faces, and the innovative strategies that are key to its continued success.
We'll explore why PD is often the preferred initial treatment, the importance of addressing patient issues, and how Hong Kong is enhancing HD support and promoting organ transplantation to ensure the long-term sustainability of this life-saving approach. This comprehensive approach offers not just financial advantages but also offers patients a better quality of life.
PD Reaches a New High
The 2024 USRDS Annual Data Report states that 14.1% of people with new end-stage renal disease (ESRD) started peritoneal dialysis (PD) in 2023, an all-time high. The report also notes that fewer than 4% of people starting ESRD treatment in 2023 received a preemptive kidney transplant. The National Institute of Diabetes and Digestive and Kidney Diseases funds the annual report, which tracks kidney disease and treatment patterns in the United States.
Individualized Prescribing
Current peritoneal dialysis guidance addresses adequacy, residual kidney function, and prescriptions for both continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. The International Society for Peritoneal Dialysis recommends a person-centred, individualized shared-decision approach. Prescriptions may be adjusted according to well-being, lifestyle, quality of life, residual kidney function, volume status, and dialytic solute removal. Clinical sources also emphasize that PD can offer greater schedule flexibility than in-center hemodialysis, but treatment must be tailored to patient needs and preferences.
A Gradual Evolution
Peritoneal dialysis has developed over time as a home-based form of kidney replacement therapy. Its evolution has involved refining treatment prescriptions, improving patient training, and addressing complications associated with long-term use. Because no historical sources were provided for this subsection, these milestones should be understood as a broad overview rather than a detailed chronology.
The 'PD-First' Policy: A Foundation for Success
The roots of Hong Kong's 'PD-first' policy trace back to 1969, with the introduction of both maintenance hemodialysis and intermittent PD. However, it was the introduction of continuous ambulatory peritoneal dialysis (CAPD) in 1980 that truly shifted the landscape. CAPD's cost-effectiveness and therapeutic benefits paved the way for PD to become the primary dialysis modality.
- Cost-Effectiveness: PD is significantly less expensive than HD, reducing the financial burden on the healthcare system.
- Improved Patient Outcomes: Studies have shown that PD can lead to better patient survival and quality of life.
- Home-Based Therapy: PD allows patients to receive treatment at home, promoting independence and reducing hospital visits.
- Enhanced Quality of Life: Patients on PD often report better mobility and freedom compared to those on HD.
Research Focuses on Safety and Durability
Recent reviews describe PD as a renal replacement therapy that removes solutes, electrolytes, and water by infusing dialysis fluid into the peritoneal cavity. Nature Reviews Nephrology reports that PD is the preferred dialysis modality for most children with ESRD and that advances in treatment have improved technique and patient survival. A 2025 narrative review highlights a continuing limitation: conventional PD fluids have a non-physiological composition that can contribute to peritoneal injury, peritoneal fibrosis, and encapsulating peritoneal sclerosis.
Flexibility Comes With Risks
PD offers flexibility and autonomy and is associated with lower costs than hemodialysis in many countries, but it can also involve unexpected treatment interruptions. Complications may be mechanical, infectious, or related to long-term treatment, and they can contribute to morbidity, technique failure, transition to hemodialysis, and death. Once patients and carers are trained in rigorous catheter-care hygiene, PD can often be performed safely and independently at home with limited specialist support. The sources therefore present PD's benefits alongside substantial requirements for training, prevention, and ongoing complication management.
Choice Depends on Circumstances
The NIDDK comparison chart evaluates hemodialysis, peritoneal dialysis, and transplantation across schedule, flexibility, diet, training, and other considerations. Hemodialysis and PD are the two main dialysis approaches for chronic kidney disease, but they work differently. Comparative outcomes can vary with patient characteristics and the healthcare organization providing treatment. A separate review specifically examines survival differences between HD and PD in adults aged 60 and older with ESRD, underscoring that modality comparisons require attention to patient age and context.
A Model for the Future of Kidney Care
Hong Kong's 'PD-first' policy offers a compelling example of how innovative healthcare strategies can improve patient outcomes, reduce costs, and enhance the overall quality of life. As the global burden of kidney disease continues to rise, the lessons learned from Hong Kong's success story provide valuable insights for healthcare providers, policymakers, and patients worldwide. By prioritizing patient-centered care and embracing the benefits of PD, we can work towards a future where the challenges of ESRD are met with effective, sustainable solutions.
A Patient-Centred Modality
PD can be understood as a flexible home-based treatment whose success depends on matching the prescription to the patient's clinical condition, lifestyle, and goals. Its advantages do not eliminate the need for training, hygiene, monitoring, and timely responses to complications. The available evidence supports a balanced interpretation: PD may expand treatment flexibility, but outcomes depend on individualized care and the support available to patients and carers.
Technology and Equity
Future PD research is expected to address safety, complications, and the lack of continuous medical oversight, which are identified barriers to wider global uptake. Emerging technologies are being developed for PD training, treatment delivery, and complication identification. Proposed directions include digital health solutions, remote monitoring, and telemedicine, while researchers also emphasize preserving residual kidney function, treating kidney-failure symptoms, and suppressing inflammation. The Clinical Kidney Journal identifies inequity of access as the modality's greatest future challenge.
Access Shapes the Choice
PD's broader impact is likely to depend not only on its clinical properties but also on whether patients can access training, supplies, monitoring, and specialist support. System capacity may influence which dialysis options are practical for different communities. Without sources specific to this subsection, these points remain general considerations rather than measured conclusions about Hong Kong or any other health system.
Care Beyond the Machine
A 2025 retrospective cohort study was designed to examine long-term PD and HD outcomes in a real-world context, reflecting the continuing need to understand how the modalities perform outside tightly controlled settings. A case report involving a 62-year-old man with kidney failure secondary to amyloidosis describes the role of dialysis nurses in managing PD failure and emphasizes that peritonitis remains a primary cause of treatment failure in continuous ambulatory PD. Newer implementation research has also evaluated an interoperable digital ecosystem connecting the Sharesource remote patient monitoring platform with the Versia electronic medical record system for people receiving automated PD at home. Together, these sources place patients, carers, nurses, and connected clinical teams at the centre of PD's real-world impact.